ViralClear Pharmaceuticals partners with Albany Molecular Research Inc. on the manufacture of merimepodib active pharmaceutic...
July 08 2020 - 1:12PM
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the
“Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc.,
today announced that it is partnering with Albany Molecular
Research Inc., (AMRI), a leading global contract research,
development and manufacturing organization (CDMO), for support in
undertaking research to investigate the potential of merimepodib to
fight SARS-CoV-2, the virus that causes COVID-19, either as a
standalone treatment or in combination with other anti-viral agents
or immune modulators.
“As part of our ongoing development and
commercialization strategy we are delighted to be working with AMRI
as our second US-based active pharmaceutical ingredient (API)
supplier. The rapid transfer, scale up and validation of
merimepodib API manufacture is key to our future supply chain and
commercialization strategy,” commented Steve King, Chief Operating
Officer, ViralClear. He continued, “ViralClear is committed to
using US-based CDMOs for the development and commercialization of
merimepodib.”
“AMRI is proud to partner with ViralClear in
this vital effort of seeking a potential treatment for COVID-19,”
said Christopher Conway, President, AMRI. “Our team is committed to
applying the expertise and experience we’re renowned for to help
combat this complex global health challenge.”
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve
signal fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
About Viral Clear Pharmaceuticals, Inc. and Merimepodib
(MMPD)
BioSig Technologies, Inc.’s (Nasdaq: BSGM) subsidiary,
ViralClear Pharmaceuticals, Inc., is seeking to develop a novel
pharmaceutical called merimepodib to treat patients with COVID-19.
Merimepodib is intended to be orally administered, and has
demonstrated broad-spectrum in vitro antiviral activity, including
strong activity against SARS-CoV-2 in cell cultures. Merimepodib
was previously in development as a treatment for chronic hepatitis
C and psoriasis by Vertex Pharmaceuticals Incorporated (Vertex),
with 12 clinical trials (7 in phase 1 and 5 in phase 2) with over
400 subjects and patients and an extensive preclinical safety
package was completed. A manuscript titled, “The IMPDH inhibitor
merimepodib provided in combination with the adenosine analogue
Remdesivir reduces SARS-CoV-2 replication to undetectable levels in
vitro”, was submitted to an online peer-reviewed life sciences
journal. This manuscript is authored by Natalya Bukreyeva, Rachel
A. Sattler, Emily K. Mantlo, John T. Manning, Cheng Huang and
Slobodan Paessler of the UTMB Galveston National Laboratory and Dr.
Jerome Zeldis of ViralClear Pharmaceuticals, Inc. (“ViralClear”) as
a corresponding author. This article highlights pre-clinical data
generated under contract with Galveston National Laboratory at The
University of Texas Medical Branch.
About AMRI
AMRI, a contract research development and
manufacturing organization, partners with the pharmaceutical and
biotechnology industries to improve patient outcomes and quality of
life. AMRI’s team combines scientific expertise and market-leading
technology to provide a complete suite of solutions in discovery,
development, analytical services, and API and drug product
manufacturing. www.amriglobal.com
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
AMRI
Kerry Hutchings
Kerry.hutchings@amriglobal.com
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Sep 2023 to Sep 2024